Takeda Pharmaceutical (NYSE:TAK) Hits New 12-Month High – Still a Buy?

Takeda Pharmaceutical Co. (NYSE:TAK) shares reached a new 52-week high during trading on Monday . The stock traded as high as $16.58 and last traded at $16.5690, with a volume of 223839 shares traded. The stock had previously closed at $16.29.

Wall Street Analyst Weigh In

TAK has been the subject of several research analyst reports. Weiss Ratings reissued a “hold (c-)” rating on shares of Takeda Pharmaceutical in a report on Monday, December 29th. Morgan Stanley started coverage on shares of Takeda Pharmaceutical in a research report on Tuesday, January 13th. They issued an “overweight” rating for the company. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold”.

Takeda Pharmaceutical Stock Performance

The company has a market cap of $53.07 billion, a PE ratio of 208.48 and a beta of 0.03. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.76 and a current ratio of 1.37. The stock’s 50-day simple moving average is $15.24 and its 200 day simple moving average is $14.76.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Thursday, October 30th. The company reported $0.44 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.44. The business had revenue of $7.30 billion for the quarter, compared to analyst estimates of $8.01 billion. Takeda Pharmaceutical had a net margin of 0.86% and a return on equity of 10.32%. Takeda Pharmaceutical has set its FY 2025 guidance at 3.250-3.250 EPS. As a group, equities analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

Institutional Trading of Takeda Pharmaceutical

Institutional investors have recently modified their holdings of the business. Capital Research Global Investors raised its position in Takeda Pharmaceutical by 0.8% in the third quarter. Capital Research Global Investors now owns 13,404,129 shares of the company’s stock worth $196,236,000 after acquiring an additional 108,556 shares in the last quarter. UBS Group AG grew its stake in shares of Takeda Pharmaceutical by 46.4% during the 3rd quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock worth $86,288,000 after purchasing an additional 1,869,323 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of Takeda Pharmaceutical by 15.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock valued at $79,120,000 after purchasing an additional 692,404 shares in the last quarter. Brandes Investment Partners LP lifted its stake in shares of Takeda Pharmaceutical by 5.9% in the second quarter. Brandes Investment Partners LP now owns 3,712,278 shares of the company’s stock valued at $57,392,000 after purchasing an additional 208,136 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its stake in shares of Takeda Pharmaceutical by 132.1% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,828,778 shares of the company’s stock valued at $41,413,000 after purchasing an additional 1,610,088 shares during the period. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.